Literature DB >> 8659800

Temperature dependence of the potency of volatile general anesthetics: implications for in vitro experiments.

N P Franks1, W R Lieb.   

Abstract

BACKGROUND: When performing experiments at room temperature with volatile general anesthetics and in vitro mammalian preparations (such as isolated neurons), the question arises as to which concentrations of anesthetics are "clinically relevant." Different choices can lead to different interpretations of the anesthetic sensitivities of putative target sites.
METHODS: Published data on the temperature dependence of minimum alveolar concentration were analyzed.
RESULTS: Although gas-phase potencies of volatile anesthetics increase markedly with decreasing temperature, the corresponding aqueous-phase potencies are relatively constant. Changes in minimum alveolar concentration with temperature can be accounted for, on physical grounds, in terms of the temperature dependencies of anesthetics binding to their central nervous system target sites.
CONCLUSION: When performing room-temperature in vitro experiments on simple mammalian preparations with a volatile anesthetic, the aqueous-phase (but not the gas- phase) minimum alveolar concentration calculated at normal body temperature is, to a first approximation, the appropriate choice for a clinically relevant anesthetic concentration. Recommended aqueous-phase minimum alveolar concentration values (in MM) for desflurane, enflurane, halothane, isoflurane, and sevoflurane have have been calculated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659800     DOI: 10.1097/00000542-199603000-00027

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  46 in total

Review 1.  General anaesthetic actions on ligand-gated ion channels.

Authors:  M D Krasowski; N L Harrison
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

2.  The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations.

Authors:  M D Krasowski; N L Harrison
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

3.  Brain activity modeling in general anesthesia: enhancing local mean-field models using a slow adaptive firing rate.

Authors:  B Molaee-Ardekani; L Senhadji; M B Shamsollahi; B Vosoughi-Vahdat; E Wodey
Journal:  Phys Rev E Stat Nonlin Soft Matter Phys       Date:  2007-10-19

4.  Anesthetic effects on fictive locomotion in the rat isolated spinal cord.

Authors:  Steven L Jinks; Jason Andrada; Omar Satter
Journal:  Neuroreport       Date:  2011-09-14       Impact factor: 1.837

5.  General anesthetics activate a nociceptive ion channel to enhance pain and inflammation.

Authors:  José A Matta; Paul M Cornett; Rosa L Miyares; Ken Abe; Niaz Sahibzada; Gerard P Ahern
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

6.  Effects of halothane on the transient outward K(+) current in rat ventricular myocytes.

Authors:  L A Davies; P M Hopkins; M R Boyett; S M Harrison
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

7.  α2-Adrenergic stimulation of the ventrolateral preoptic nucleus destabilizes the anesthetic state.

Authors:  Hilary S McCarren; Michael R Chalifoux; Bo Han; Jason T Moore; Qing Cheng Meng; Nina Baron-Hionis; Madineh Sedigh-Sarvestani; Diego Contreras; Sheryl G Beck; Max B Kelz
Journal:  J Neurosci       Date:  2014-12-03       Impact factor: 6.167

8.  Novel activation of voltage-gated K(+) channels by sevoflurane.

Authors:  Annika F Barber; Qiansheng Liang; Manuel Covarrubias
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

9.  Isoflurane inhibits the neurotransmitter release machinery.

Authors:  Bruce E Herring; Zheng Xie; Jeremy Marks; Aaron P Fox
Journal:  J Neurophysiol       Date:  2009-06-10       Impact factor: 2.714

10.  General anesthetic actions on GABA(A) receptors.

Authors:  Paul S Garcia; Scott E Kolesky; Andrew Jenkins
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.